EP4728074A2 - Systeme, verfahren und zusammensetzungen zur unterdrückung von pkd1 - Google Patents

Systeme, verfahren und zusammensetzungen zur unterdrückung von pkd1

Info

Publication number
EP4728074A2
EP4728074A2 EP24824193.7A EP24824193A EP4728074A2 EP 4728074 A2 EP4728074 A2 EP 4728074A2 EP 24824193 A EP24824193 A EP 24824193A EP 4728074 A2 EP4728074 A2 EP 4728074A2
Authority
EP
European Patent Office
Prior art keywords
polynucleotide
binding domain
sequence
seq
grna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24824193.7A
Other languages
English (en)
French (fr)
Inventor
Demetrios Samuel MAXIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nephrogen Inc
Original Assignee
Nephrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nephrogen Inc filed Critical Nephrogen Inc
Publication of EP4728074A2 publication Critical patent/EP4728074A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24824193.7A 2023-06-13 2024-06-13 Systeme, verfahren und zusammensetzungen zur unterdrückung von pkd1 Pending EP4728074A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472794P 2023-06-13 2023-06-13
PCT/US2024/033918 WO2024259175A2 (en) 2023-06-13 2024-06-13 Systems, methods, and compositions for de-repressing pkd1

Publications (1)

Publication Number Publication Date
EP4728074A2 true EP4728074A2 (de) 2026-04-22

Family

ID=93852799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24824193.7A Pending EP4728074A2 (de) 2023-06-13 2024-06-13 Systeme, verfahren und zusammensetzungen zur unterdrückung von pkd1

Country Status (2)

Country Link
EP (1) EP4728074A2 (de)
WO (1) WO2024259175A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4680746A1 (de) * 2023-06-16 2026-01-21 Pyc Therapeutics Limited Zusammensetzungen und verfahren zur behandlung von nierenerkrankungen
WO2025196338A1 (en) * 2024-03-22 2025-09-25 Helex Inc. Methods and compositions for the treatment of autosomal dominant polycystic kidney disease
WO2025208171A1 (en) * 2024-04-04 2025-10-09 PYC Therapeutics Limited Advanced compositions and methods for treatment of kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395781C (en) * 2000-07-13 2010-04-13 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
EP4176434A4 (de) * 2020-05-29 2024-09-11 The General Hospital Corporation Systeme und verfahren zur stabilen und heritablen veränderung durch präzisionsbearbeitung (form)

Also Published As

Publication number Publication date
WO2024259175A2 (en) 2024-12-19
WO2024259175A3 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
US11492670B2 (en) Compositions and methods for targeting cancer-specific sequence variations
EP4728074A2 (de) Systeme, verfahren und zusammensetzungen zur unterdrückung von pkd1
CN108473527A (zh) 用于消除免疫抑制疗法期间jc病毒激活和pml(进行性多灶性白质脑病)风险的基因编辑方法和组合物
CN110869498A (zh) 经由核递送crispr/cas9导向编辑细胞rna
KR20160097331A (ko) 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
WO2016094874A1 (en) Escorted and functionalized guides for crispr-cas systems
EP3080260A1 (de) Crispr-cas-systeme und verfahren zur veränderung der expression von genprodukten, strukturelle informationen und induzierbare modulare cas-enzyme
JP2024506910A (ja) 操作された細胞外小胞およびそれらの使用
JP2023527464A (ja) ＳＡＲＭ１の両対立ｋ遺伝子ノックアウト
EP4558629A2 (de) Biallelisches knockout von angptl3
EP4612291A1 (de) Zusammensetzungen und verfahren zur exzision der vermehrung von transkriptionsfaktor 4 (tcf4)-repeats
EP4335924A1 (de) Ultrareine minivektoren für gentherapie
US20260085331A1 (en) Biallelic Knockout of PDCD1
WO2025227064A1 (en) Genomic editing methods to treat cardiovascular disease, and compositions for use in practicing the same
KR20240027748A (ko) Rbm20 돌연변이의 게놈 편집
AU2023347821A1 (en) Biallelic knockout of hla-e
WO2024064607A9 (en) Biallelic knockout of tet2
WO2024064623A2 (en) Biallelic knockout of cish
WO2024064683A2 (en) Biallelic knockout of ciita
CA3026112A1 (en) Cpf1 complexes with reduced indel activity

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR